Whitehawk Therapeutics, Inc. SEC filings WHWK
Whitehawk Therapeutics, Inc. has 671 filings in SEC EDGAR's recent list, going back to Feb 1, 2008. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 6, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Sep 10, 2026 (officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jun 9, 2026 | — |
| CORRESP | Letter to the SEC | Jun 5, 2026 | — |
| UPLOAD | Letter from the SEC | Jun 5, 2026 | — |
| UPLOAD | Letter from the SEC | May 22, 2025 | — |
| CORRESP | Letter to the SEC | May 13, 2025 | — |
| UPLOAD | Letter from the SEC | May 7, 2025 | — |
| EFFECT | Filing | Apr 8, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2025 | — |
| D | Filing | Mar 18, 2025 | — |
| EFFECT | Filing | Apr 30, 2024 | — |
| CORRESP | Letter to the SEC | Apr 26, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 20, 2024 | — |
| EFFECT | Filing | Nov 4, 2022 | — |
| CORRESP | Letter to the SEC | Nov 2, 2022 | — |
| UPLOAD | Letter from the SEC | Nov 1, 2022 | — |
| D | Filing | Oct 11, 2022 | — |
| EFFECT | Filing | Oct 1, 2021 | — |
| CORRESP | Letter to the SEC | Sep 30, 2021 | — |
| UPLOAD | Letter from the SEC | Sep 29, 2021 | — |
| D | Filing | Sep 10, 2021 | — |
| D | Filing | Sep 10, 2021 | — |
| EFFECT | Filing | Apr 15, 2021 | — |
| CORRESP | Letter to the SEC | Apr 13, 2021 | — |
| UPLOAD | Letter from the SEC | Apr 12, 2021 | — |
| EFFECT | Filing | Feb 12, 2019 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2019 | — |
| CORRESP | Letter to the SEC | Feb 8, 2019 | — |
| EFFECT | Filing | Sep 18, 2018 | — |
| CORRESP | Letter to the SEC | Sep 14, 2018 | — |
| UPLOAD | Letter from the SEC | Sep 11, 2018 | — |
| CT ORDER | Filing | Jul 24, 2018 | — |
| CERT | Filing | Jun 25, 2018 | — |
| 8-A12B | Filing | Jun 25, 2018 | — |
| EFFECT | Filing | Apr 11, 2018 | — |
| CORRESP | Letter to the SEC | Apr 9, 2018 | — |
| EFFECT | Filing | Jun 23, 2017 | — |
| CORRESP | Letter to the SEC | Jun 21, 2017 | — |
| CORRESP | Letter to the SEC | Jun 9, 2017 | — |
| UPLOAD | Letter from the SEC | Jun 8, 2017 | — |
| CORRESP | Letter to the SEC | May 22, 2017 | — |
| UPLOAD | Letter from the SEC | May 15, 2017 | — |
| D | Filing | Mar 30, 2017 | — |
| DEFM14C | Filing | Mar 27, 2017 | — |
| PREM14C | Filing | Mar 17, 2017 | Mar 16, 2017 |
| SC 14F1 | Filing | Feb 24, 2017 | — |
| 10QSB | Filing | Aug 11, 2008 | Jun 30, 2008 |
| 10QSB | Filing | May 15, 2008 | Mar 31, 2008 |
| 10SB12G | Filing | Feb 1, 2008 | — |
Showing 49 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- WHWK (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Morristown, NJ
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1422142
- Former names
- Aadi Bioscience, Inc. (until Mar 18, 2025); Aerpio Pharmaceuticals, Inc. (until Aug 23, 2021); ZETA ACQUISITION CORP II (until Mar 13, 2017)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.